Pulmonx reports trial results for emphysema treatment system

Pulmonx (LUNG) reported CONVERT Trial results for its AeriSeal System in severe emphysema patients, showing 75.8% success in converting collateral ventilation status. Treated patients achieved 88.9% target lobe volume reduction at 45 days, with improvements in lung function and quality of life. The company is enrolling patients in the CONVERT II Pivotal Trial for U.S. FDA approval.

Original reporting
Published Nov 17, 2026, 12:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 12:29 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefTechnology
Primary signal
$LUNG
Bullish
medium confidence
Mentioned
$LUNG
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$LUNGBullishMed
01

Why it matters

The publication of CONVERT Trial results provides concrete efficacy endpoints and supports the rationale for ongoing CONVERT II enrollment and the planned US PMA application timeline.

02

Market read

For LUNG, the key trading relevance is the newly published efficacy endpoints that strengthen the evidence narrative ahead of CONVERT II and the FDA PMA submission.

03

What to watch

Traders may discount the impact if the article does not include safety/tolerability details, durability beyond 12 months, or comparative performance versus existing collateral-ventilation assessment approaches.

Relevance 7/10Novelty 7/10Timing: today, following publication of CONVERT Trial results

Background

Pulmonx is evaluating the AeriSeal System to identify and convert collateral ventilation status in severe emphysema patients, with Zephyr Endobronchial Valves used after successful conversion.

Company-level read

Ticker impact

$LUNGBullishMedium confidence
Context

Pulmonx published CONVERT Trial results for its AeriSeal System, reporting 75.8% conversion to collateral ventilation negative status and subsequent Zephyr valve outcomes.

Expected impact

Likely upward bias as traders price improved probability of regulatory progress and clearer patient-selection benefit for Zephyr valve therapy.

Evidence & confidence

The article discloses specific trial endpoints (conversion rate and 45-day/12-month lobe volume reduction) and ties them to the planned PMA support timeline, which can move biotech/device sentiment even without an approval decision.

Market effects

Reinforces the broader endobronchial valve ecosystem’s emphasis on collateral ventilation assessment and patient-selection, potentially affecting sentiment across lung-device peers.

Limited direct regional read-through; trial sites are Europe and Australia but the commercial/regulatory pathway is US-focused.

Moderate global relevance for interventional pulmonology, mainly through evidence quality and regulatory-readiness signals.

Counterpoint

Published results may not change near-term valuation if investors already expected CONVERT data, and the key remaining catalyst is CONVERT II and FDA PMA acceptance rather than publication alone.

Key entities

  • Pulmonx Corporation

    NASDAQ-listed medical device company developing the AeriSeal System and Zephyr Endobronchial Valves for severe emphysema.

  • AeriSeal System

    Device evaluated in the CONVERT Trial to convert collateral ventilation positive lobes to collateral ventilation negative status.

  • Zephyr Endobronchial Valves

    Valves used after AeriSeal conversion to achieve target lobe volume reduction.

  • CONVERT Trial

    101-patient, 14-site Europe and Australia trial published in Respiration: International Journal of Thoracic Medicine.

  • CONVERT II Pivotal Trial

    Ongoing multicenter study designed to enroll about 200 patients to support a US PMA application, with six-month results intended for FDA support.

Related articles

$GMABHighAI 8/10

Biotech Stocks Rise: GMAB Surges, LUNG And AXGN Gain Over 30%

Genmab (GMAB) shares rose 33% after reporting positive Phase 3 results for its cancer drug. Pulmonx (LUNG) and Axogen (AXGN) shares gained over 30% on strong quarterly results. OrthoPediatrics (KIDS) and Replimune (REPL) also reported improved financials, driving their stock prices up. Specific financial data and guidance were provided by each company.

$LUNGHigh

Pulmonx (LUNG) Q3 2026 Earnings Call Transcript

Pulmonx (LUNG) reported Q3 2026 revenue of $22.8M, up 6% YoY, marking a return to growth. U.S. revenue rose 7% to $14.9M, while international revenue increased 5% to $7.9M. The company reduced adjusted EBITDA loss by 60% to $3.5M and expects full-year revenue of $90M-$92M. Gross margin improved to 76%, and operating expenses decreased 18% YoY to $24.9M. Pulmonx aims to expand its market through AeriSeal and restart commercial activity in China.

$LUNGMed

Pulmonx Reports Third Quarter 2026 Financial Results

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Pulmonx Reports Third Quarter 2026 Financial Results Redwood City, CA - October 27, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the thi